Topic guide
Articles and reference material connected to this topic, organised for clear reading.
Reading path
Dive Brief: - Horizon Pharma is pursuing a hostile bid of $3 billion for Depomed. - Although Horizon has been purusing Depomed since March, the latter firm has continuously rejected Horizon's offers. - Depomed…
Read guide →Dive Brief: - Horizon Pharma has backed off of its unsolicited bid for Depomed after a California court found the company guilty of using confidential information improperly. - Charges of inappropriate use of …
Read guide →Horizon Pharma said today it will acquire rights to interferon gamma-1b outside of North America and Japan from Boehringer Ingelheim for €25 million ($28 million). The deal gives Horizon Pharma global rights t…
Read guide →Horizon Pharma withdrew its offer to acquire Depomed after a California state court sided with Depomed in its legal battle against the unsolicited bid. As of yesterday, when the withdrawal was announced, the v…
Read guide →Horizon Pharma has acquired the U.S. sales and marketing rights to osteoarthritis (OA) drug Pennsaid® (diclofenac sodium topical solution) 2% w/w (Pennsaid 2%) from Nuvo Research for a one-time cash payment of…
Read guide →Trial with interferon gamma-1b missed primary and secondary endpoints Horizon Pharma is axing further development of its interferon gamma-1b protein therapy Actimmume® for the Friedreich’s ataxia (FA) indicati…
Read guide →